We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

I'm ok with this

Intac Case Study | Focus Areas | R&D | Grünenthal Group

Raising the hurdle for abuse: INTAC®

The powerful combination of technology and medicines plays a key role in driving innovation, so devices and technologies are a major development focus for us.

INTAC® is the Abuse Deterrent Formulation (ADF) technology that we pioneered to raise the hurdle for abuse of opioids and other drugs with abuse potential. Representing an innovative approach to reducing the abuse of prescription medicines, the technology offers extraordinary mechanical strength that makes pills very hard to crush up and abuse via methods such as snorting or injecting.

Watch a video about INTAC®

The INTAC® technology can be customised to a variety of dosage forms, active ingredients, and release profiles from minutes up to 24 hours. The immense flexibility of the INTAC® platform reflects our commitment to developing devices and technologies that deliver true benefits to patients.

In February 2016, we entered into a strategic agreement with Patheon, a collaboration that enables us to capitalise on their specialist technical manufacturing capabilities to bring new therapies to market made using the INTAC® technology.

We are looking to work with licensing partners in the U.S. to grow the portfolio of products that use INTAC® for a variety of conditions. The typical collaboration model that we are looking for includes the joint, US-centred development of a product-technology combination up to approval.